Steven Seedhouse
Stock Analyst at Raymond James
(3.54)
# 864
Out of 4,667 analysts
161
Total ratings
44.16%
Success rate
6.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $20.77 | +169.62% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $7.98 | +514.04% | 10 | Nov 8, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $3.67 | +281.47% | 6 | Oct 29, 2024 | |
| QTTB Q32 Bio | Initiates: Strong Buy | $90 | $27.28 | +229.91% | 1 | Oct 24, 2024 | |
| KRRO Korro Bio | Initiates: Strong Buy | $153 | $47.00 | +225.53% | 1 | Oct 21, 2024 | |
| WVE Wave Life Sciences | Upgrades: Strong Buy | $13 → $22 | $14.26 | +54.28% | 2 | Oct 16, 2024 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $116 → $118 | $51.53 | +128.99% | 17 | Jul 25, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $93 | $88.63 | +4.93% | 9 | Jul 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $45.75 | +48.63% | 3 | May 10, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $27.49 | +285.59% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $4.92 | +204.88% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $29.99 | +86.73% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $43.69 | +46.49% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $2.59 | +575.68% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.12 | +334.45% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $21 → $19 | $2.04 | +831.37% | 13 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $2.90 | +658.62% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.41 | +605.39% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $13.04 | +168.40% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $44.05 | -13.73% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $43.65 | +62.66% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.70 | +617.88% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $20.31 | +87.10% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $16.17 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.96 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $156.00 | - | 2 | Apr 23, 2020 |
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $20.77
Upside: +169.62%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $7.98
Upside: +514.04%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $3.67
Upside: +281.47%
Q32 Bio
Oct 24, 2024
Initiates: Strong Buy
Price Target: $90
Current: $27.28
Upside: +229.91%
Korro Bio
Oct 21, 2024
Initiates: Strong Buy
Price Target: $153
Current: $47.00
Upside: +225.53%
Wave Life Sciences
Oct 16, 2024
Upgrades: Strong Buy
Price Target: $13 → $22
Current: $14.26
Upside: +54.28%
Viking Therapeutics
Jul 25, 2024
Maintains: Strong Buy
Price Target: $116 → $118
Current: $51.53
Upside: +128.99%
Gilead Sciences
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $88.63
Upside: +4.93%
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $45.75
Upside: +48.63%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $27.49
Upside: +285.59%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $4.92
Upside: +204.88%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $29.99
Upside: +86.73%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $43.69
Upside: +46.49%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $2.59
Upside: +575.68%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.12
Upside: +334.45%
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $2.04
Upside: +831.37%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $2.90
Upside: +658.62%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.41
Upside: +605.39%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $13.04
Upside: +168.40%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $44.05
Upside: -13.73%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $43.65
Upside: +62.66%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.70
Upside: +617.88%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $20.31
Upside: +87.10%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $16.17
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.96
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $156.00
Upside: -